Red Arrow Therapeutics is focused on developing innovative cancer therapies through the use of nanopolymer drug delivery systems. Their primary technology involves the creation of nanopolymer cytokine micelles (NCM) that can stably and efficiently load biologics, such as the pro-inflammatory cytokine IL-12. These micelles are designed to remain inactive until they reach the tumor microenvironment, where a pH change triggers the release of the biologics. This targeted delivery mechanism aims to minimize off-target toxicity while maximizing therapeutic efficacy, particularly for patients with solid tumors who are often unresponsive to conventional immunotherapies.

The company’s lead asset, RA001, is based on this novel approach and is expected to enter Investigational New Drug (IND) application processes by 2027. Red Arrow Therapeutics aims to leverage its nanopolymer technology not only for standalone treatments but also in combination with existing immuno-checkpoint inhibitors, potentially enhancing the effectiveness of therapies for the 80% of solid tumor patients who currently do not respond to standard immunotherapy. This innovative strategy positions Red Arrow Therapeutics at the forefront of cancer treatment advancements, with a vision to make these life-saving therapies accessible worldwide.

United States

Red Arrow Therapeutics, Inc. is a biotechnology company focusing on developing new technologies that can turn "cold" tumors into inflamed "hot" tumors. Red Arrow Therapeutics' lead product candidate, RA-001, a pH-activated polymer micelle loaded with IL-12, is designed to release fully active IL-12 upon sensing intratumoral pH to safely potentiate immunotherapy. 
In the current pre-clinical data, RA-001 exhibits strong anti-tumor immunity in various tumor models. Furthermore, RA-001 shows high efficacy as monotherapy and in combination with immune checkpoint inhibitors.

Red Arrow Therapeutics

Company Details